Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756364 · ClinicalTrials.gov registry record · Phase 2
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
A Phase 2 study, sponsored by Calithera Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT02756364 is a Phase 2 study that has completed, run by Calithera Biosciences. The registered enrollment target is 141 participants.
The verdict
NCT02756364, a Phase 2 study, has completed, sponsored by Calithera Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.
Interventions
- DRUG Fulvestrant
- DRUG Sapanisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2016-07-28 |
| Est. Completion | 2019-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756364
The ClinicalTrials.gov registry entry for NCT02756364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT02756364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756364 about?
NCT02756364 is a clinical study titled "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy". The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.
What is the current status of trial NCT02756364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2016-07-28. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT02756364?
The interventions under investigation include: Fulvestrant (DRUG), Sapanisertib (DRUG).
Who is sponsoring clinical trial NCT02756364?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.